NASDAQ:AMLX

Amylyx Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy AMLX

*Your capital is at risk

$13.20

-0.0900 (-0.677%)

At Close: Jun 03, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

10:00am, Sunday, 15'th Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Com

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

10:00am, Thursday, 12'th Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Com

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

10:08am, Wednesday, 11'th Jun 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) b

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

10:00am, Tuesday, 10'th Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

10:00am, Sunday, 08'th Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

10:00am, Thursday, 05'th Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

10:00am, Tuesday, 03'rd Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

07:00am, Tuesday, 03'rd Jun 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

10:00am, Sunday, 01'st Jun 2025

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

10:05am, Thursday, 29'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

10:00am, Sunday, 25'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

10:00am, Thursday, 22'nd May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

07:00am, Wednesday, 21'st May 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences.

Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?

11:01am, Tuesday, 20'th May 2025

The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 105.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

10:00am, Tuesday, 20'th May 2025

NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Comp

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by